RxDoctor Payments DataLook up a doctor →

Sanjay Rathi, MD

Neurological Surgery · North Haven, CTNPI 1821007972

Payments from drug & device makers

$540,826in general payments, 2019–2025

Across 1,277 payments — averaging $423.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$201K
  • EMD Serono, Inc.$196K
  • Neurocrine Biosciences, Inc.$64K
  • Amneal Pharmaceuticals LLC$24K
  • Axsome Therapeutics, Inc.$10K
  • Kyowa Kirin, Inc.$8K
  • plus $38K from 50 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)383$201,255
EMD Serono, Inc.332$195,824
Neurocrine Biosciences, Inc.85$63,665
Amneal Pharmaceuticals LLC50$23,997
Axsome Therapeutics, Inc.8$10,229
Kyowa Kirin, Inc.20$7,720
Bristol Myers Squibb51$7,334
E.r. Squibb & Sons, L.L.C.15$7,214
Sanofi14$4,451
Novartis67$2,836
Amgen(2 entities)22$1,346
Biogen24$1,243
Lundbeck LLC27$949
Genentech, Inc.11$893
Eisai Inc.13$876
SK Life Science, Inc.8$860
Teva Pharmaceuticals USA, Inc.8$781
Genentech USA, Inc.12$777
Johnson & Johnson7$604
MDD US Operations, LLC9$577
UCB, Inc.8$546
Mallinckrodt Hospital Products Inc.15$514
TG Therapeutics, Inc.4$512
Neurelis, Inc.8$474
Argenx US, Inc.4$402
Biohaven Pharmaceuticals, Inc.8$392
Ipsen Biopharmaceuticals, Inc11$387
Jazz Pharmaceuticals Inc.3$369
Alnylam Pharmaceuticals Inc.3$321
Lilly USA, LLC3$274
Abbott2$263
Otsuka America Pharmaceutical, Inc.2$250
Acadia Pharmaceuticals Inc3$224
Sumitomo Pharma America, Inc.2$143
Merz Pharmaceuticals, LLC2$140
ANI Pharmaceuticals, Inc.2$140
Biohaven Pharmaceutical Holding Company Ltd.2$139
Vanda Pharmaceuticals Inc.1$125
AstraZeneca1$125
Impel Pharmaceuticals Inc.1$125
Sunovion Pharmaceuticals Inc.3$125
Avanir Pharmaceuticals, Inc.1$124
Amylyx Pharmaceuticals, Inc.1$122
Akcea Therapeutics, Inc.1$120
Avadel CNS Pharmaceuticals, LLC1$119
Pfizer2$118
Acorda Therapeutics, Inc1$115
Grifols USA, LLC1$96
Promius Pharma LLC1$94
Medtronic1$94
Sanofi-aventis U.S. LLC1$92
Cycle Pharmaceuticals Inc1$80
Supernus Pharmaceuticals, Inc.4$66
Adamas Pharmaceuticals, Inc.1$64
Strongbridge US Inc.4$62
Xeris Pharmaceuticals, Inc.2$38

How this compares

$540,826 in reported general payments places this provider in the 95th percentile of 94 neurological surgery providers in Connecticut.

See all neurological surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$137,617
Medicare patients
71
Services billed
17,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurological surgery in North Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →